Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
Convalescent plasma with high SARS-CoV-2 antibody titers can help prevent progression to severe COVID-19 in older adults with mild disease, according to a New England Journal of Medicine study.
Some 160 adults aged 65 and older in Argentina who tested positive for SARS-CoV-2 within 48 hours of developing mild COVID-19 symptoms (e.g., fever, dry cough, fatigue) were randomized to receive an infusion of high-antibody-titer convalescent plasma (IgG above 1:1000 against SARS-CoV-2 spike protein) or placebo. Infusions were given within 72 hours of symptom onset and lasted about 1.5–2.0 hours.
The primary endpoint — development of severe respiratory disease by day 15 — was roughly halved with plasma infusion (16% of plasma recipients vs. 31% of placebo recipients). The researchers calculated that seven older patients would need to be treated to prevent one case of severe respiratory disease.
Dr. Richard Saitz, associate editor with Physician's First Watch, points out that it may be a challenge to disseminate these infusions widely.
Comment
LINK(S):
NEJM article (Free)
NEJM Journal Watch COVID-19 page (Free)
NEJM COVID-19 page (Free)